# A Study of RO5212054 (PLX3603) in Participants With BRAF V600-Mutated Advanced Solid Tumors

> **NCT01143753** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 45 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** RO5212054

## Key facts

- **NCT ID:** NCT01143753
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07-27
- **Primary completion:** 2012-06-30
- **Final completion:** 2017-05-02
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2017-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01143753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01143753, "A Study of RO5212054 (PLX3603) in Participants With BRAF V600-Mutated Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01143753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*